Arcensus

It’s official: The College of American Pathologists (CAP) has awarded accreditation to Arcensus, and we’re incredibly proud of this milestone. As one of the gold standards in laboratory testing, CAP accreditation underscores our continuous commitment to delivering the highest quality, accuracy, and reliability in diagnostics through Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES). A huge thank you to our dedicated team for making this possible! Together, we are setting the bar for diagnostic excellence. #QualityMatters #CAPAuditSuccess #WGS #WES #DiagnosticExcellence

We would like to introduce Dr. Alexandru Popa, who has been appointed as the new CEO of Arcensus GmbH. With over 20 years of experience in healthcare, Dr. Popa brings valuable expertise in pharmaceuticals and diagnostic testing. In his new role, Dr. Popa will drive company growth through increased focus on business development and commercial operations. He will also strengthen our focus on delivering high-quality genomic data and comprehensive reports that empower patients and healthcare providers alike through our key products, mylifeGenome, mylifeExome, and Data2Report. Visit our homepage for the full announcement: https://lnkd.in/dr2TyNXd #Genomics #WGS #WES #DataDrivenInsights

Duchenne Muscular Dystrophy (DMD) is the most common form of childhood muscular dystrophy and typically affects males. Did you know that 1 in 5,000 boys worldwide are born with DMD, yet it often takes 2.5 years from the first symptoms to receive a diagnosis? The current average age of diagnosis is 4.5 years. For the upcoming World Duchenne Awareness Day on Sep 7th, let’s recognize the signs, advocate for early intervention, and help reduce the time to diagnosis for children with DMD. We can make a difference by spreading awareness and promoting early genetic testing. To learn more about this rare genetic disease, we recommend this very well-produced 3 min video: https://lnkd.in/eNAb-zpK #WDAD2024 #DuchenneAwareness #KnowledgeIsPower #GeneticHealth

  We're relocating to a new office by the Baltic Sea in Warnemünde's Biotechnology Park! Starting August 1st, 2024, you can find us at Friedrich Barnewitz Str. 9, 18119 Rostock, Germany.   Our growth requires more space to expand our team and advance genomic insights. Visit our homepage to schedule a tour of our new office! #Expansion #GenomicInsights #WholeGenomeSequencing #WholeExomeSequencing

Don’t miss our upcoming webinar this Thursday to - Gain insights into secondary findings - Discover the value of secondary findings in cardiovascular disease - Learn to manage patients and relatives with CVD-related secondary findings Click below to register for the webinar! #CVD #Cardiology #GeneticTesting #Secondaryfindings #HealthcareEducation

We have launched our Arcensus monthly newsletter! Subscribe for educational resources, in-depth articles, expert opinions, case studies and more here: https://lnkd.in/dmPqu3u8   #Arcensusnewsletter #genomicsnews

Join our upcoming webinar and register here: https://lnkd.in/ekwy4QRc We will explore: - The difference between secondary and incidental findings - Secondary findings in cardiology - Family history and genetic testing results in the diagnostic evaluation - Impact and uncertainties of genetic testing - Current clinical guidelines and their implications Don’t miss this chance to expand your knowledge and stay updated with the latest guidelines! #GeneticsWebinar #Cardiology #GeneticTesting #ClinicalGuidelines #HealthcareEducation

Have you seen the recent paper by Chi et al. (PMID: 38789118) demonstrating the impact of reanalysis on diagnostic yield? By re-evaluating existing WGS data with the latest techniques and knowledge, we can boost diagnostic yields through the detection of new gene-disease relationships, variant classification and clinical updates over time. Reanalysis found a diagnostic variant in 28% of previously negative cases. This means more accurate diagnoses, better-informed treatment plans, and improved patient outcomes. #Genomics #WGSreevaluation #PrecisionMedicine #ChiRenTsai

Reflecting on a successful #ESHG2024: It was a great opportunity to share our latest research, which sparked great discussions and collaborations. A big thank you to our colleagues and to everyone who stopped by to chat with our team. We're excited to continue advancing the field of genomics!

Excited to share another poster at #ESHG2024! Join us as we present our latest discovery: a novel missense variant in the SVBP gene causing neurodevelopmental disorders with microcephaly.    Don't miss Poster P11.052.C and the opportunity to meet Gabriela Elena Oprea, Dr. rer. nat.!   #GeneticResearch #NeurodevelopmentalDisorders #SVBP